Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9

Date Issued
2008
Author(s)
Sachse-Seeboth, C.
Pfeil, J.
Sehrt, D.
Meineke, I.
Bruns, E.
Vormfelde, S. V.
DOI
10.1038/clpt.2008.213
Abstract
The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered Δ9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9 2 allele status. However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9 3/ 3 homozygotes than in CYP2C9 1/ 1 homozygotes. CYP2C9 3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9 3 variant may influence both the therapeutic and adverse effects of THC.
File(s)
No Thumbnail Available
Name

Sachse-Seeboth.pdf

Description
closedAccess
Size

1.17 MB

Checksum (MD5)

f9f64635150000e6214de752c33a7cc4

Request a copy